Seroprevalence of HTLV-1 and HTLV-2 among intravenous drug users and persons in clinics for sexually transmitted diseases.
about
Long-term increases in lymphocytes and platelets in human T-lymphotropic virus type II infectionInternational Retrovirology Association brings together scientists and clinicians to bridge discoveries about human T-lymphotropic viruses from the laboratory to clinical trials.Increased mortality associated with HTLV-II infection in blood donors: a prospective cohort studyRetroviral coinfections: HIV and HTLV: taking stock of more than a quarter century of researchTransmission of Tropical and Geographically Restricted Infections during Solid-Organ TransplantationRole of accessory proteins of HTLV-1 in viral replication, T cell activation, and cellular gene expression.Intrahost variations in the envelope receptor-binding domain (RBD) of HTLV-1 and STLV-1 primary isolates.Clinical outcomes and disease progression among patients coinfected with HIV and human T lymphotropic virus types 1 and 2.Prevalence of HTLV types I and II among drug users in King County, Washington.Expression of glucose transporter 1 confers susceptibility to human T-cell leukemia virus envelope-mediated fusion.Non-malarial infectious diseases of antenatal care in pregnant women in Franceville, Gabon.Seroprevalence of human T-lymphotropic virus antibodies among patients with lymphoid malignancies at a tertiary center in Lagos, Nigeria.Mother-to-Child Transmission of Human T-Cell Lymphotropic Viruses-1/2: What We Know, and What Are the Gaps in Understanding and Preventing This Route of Infection.Seroprevalence of human T lymphotropic virus antibodies among healthy blood donors at a tertiary centre in Lagos, Nigeria.Integrase inhibitors effective against human T-cell leukemia virus type 1Human T-cell lymphotropic virus type 1 exposures following blood-borne virus incidents in central Australia, 2002-2012.Molecular determinants of human T-lymphotropic virus type 1 transmission and spread.In vivo analysis of replication and immunogenicity of proviral clones of human T-lymphotropic virus type 1 with selective envelope surface-unit mutations.Cellular Factors Involved in HTLV-1 Entry and PathogenicitGlobal epidemiology of HTLV-I infection and associated diseases.Prevalence of human T-cell lymphotropic virus type 1 (HTLV-1) and HTLV-2 infection among Spanish drug users measured by HTLV-1 assay and HTLV-1 and -2 assay. HTLV-1 and HTLV-2 Spanish Study GroupComplete nucleotide sequence of an Amerindian human T-cell lymphotropic virus type II (HTLV-II) isolate: identification of a variant HTLV-II subtype b from a Guaymi IndianIdentification and characterization of an extended Tax protein in human T-cell lymphotropic virus type II subtype b isolates.Detection of antibodies to trans-activator protein (p40taxI) of human T-cell lymphotropic virus type I by a synthetic peptide-based assay.Evaluation of an immunoblot assay for serological confirmation and differentiation of human T-cell lymphotropic virus types I and II.HTLV-2 infection in injection drug users in King County, WashingtonRisk factors for HTLV-II infection in Peruvian men who have sex with menUse of dried blood spots for the detection and confirmation of HTLV-I specific antibodies for epidemiological purposes.Infection with human T-lymphotropic virus types-1 and -2 (HTLV-1 and -2): Implications for blood transfusion safety.Upregulation of HTLV-1 and HTLV-2 expression by HIV-1 in vitro.Seroprevalence and demographic determinants of human T-lymphotropic virus type 1 and 2 infections among first-time blood donors--United States, 2000-2009.Sexual transmission of human T-cell lymphotropic virus type 1.Cancer surveillance series: non-Hodgkin's lymphoma incidence by histologic subtype in the United States from 1978 through 1995.Estimation of the infectious viral load required for transfusion-transmitted human T-lymphotropic virus type 1 infection (TT-HTLV-1) and of the effectiveness of leukocyte reduction in preventing TT-HTLV-1.Seroepidemiology of human T-cell lymphotropic virus among Iranian adult thalassemic patients.Infectious Causes of Malignancy.Risk factors for human T cell lymphotropic virus type I among injecting drug users in northeast Brazil: possibly greater efficiency of male to female transmission.HTLV-I infection among relatives of patients with adult T-cell leukemia/lymphoma in Brazil: analysis of infection transmission.HTLV-I and HTLV-II infections in subjects at risk for HIV-I infection from southeastern Italy (Apulia region).Evidence for sexual transmission of HTLV-II in Spain.
P2860
Q24658333-989E4CA6-D72D-4125-80E6-99CB7C594AC2Q24796407-2227EC16-8A79-4D22-8CC0-2B1D6DA59771Q24804881-BC3C0194-40DD-4DC0-A110-115EAE0702FCQ26853678-E793086D-DBCC-44A9-97AC-15646F546CB8Q27485255-AB930E75-181F-447C-9A68-C3A71D1DC24CQ33206633-52C619A2-580F-448E-A28C-F64D926C42B2Q33244717-E43F05F4-ABD7-4138-BFE0-E65AEA64F897Q33362127-7AD57103-ECF7-4CE5-9813-57D3B52F66C2Q33607952-EF8F4024-7EAE-413B-BD3A-62E570819B11Q33707390-A6D1454A-B0A2-4AC8-BD7D-7111838073E6Q33792257-EC27DDD3-9027-4CB3-BDA3-D9521AC62B95Q34166953-CDAB2239-3093-4F04-A282-A7E2EFF060D4Q34181725-56BE6CD3-EE8D-4741-BC60-9F38C6D3050BQ34344269-37458E23-1001-4B59-8A2E-1130A987B12FQ34932350-27ECB9B1-E913-4B46-A086-27EF0090176DQ35008382-8D21ABA7-5E87-45A2-971E-665DB279592DQ35261463-608D1AFF-1C20-4078-8570-AD4E723F4D28Q35847684-05CBCEA4-B5FC-4864-8C04-8669B7D98F5FQ36049779-93F70652-81F0-4C19-9900-31C8CE73BD32Q36254899-03007C84-E484-454C-B121-8282D13519C1Q36523121-87803EEF-50B5-4E13-B110-A587E8F6F702Q36651029-6EAA7F23-0A64-4B93-B37C-013D221D088BQ36655586-F989AD9F-CFE0-4BB3-A5A4-3061979113E2Q36928013-33CD3338-5F8C-4568-BA67-6E042696500FQ37063773-CE651569-1BD4-480A-AD04-E9A0C199661BQ37196486-8FBE1438-748C-4421-B6A8-CB4A40FA242CQ37226452-7A42A93E-544A-4F65-9A50-527365FD91E6Q37268551-AB2BC4FB-1214-4F90-B6DD-F1033B961E51Q37296863-4CDB6AD8-0717-483A-9470-D600656F5D45Q37403269-77A23CD5-545B-4A2E-87A5-C555AA502CF4Q37520190-755BE8C8-AF99-4C14-B777-F8F876B56E8BQ38235269-BB1F636F-67F4-4F4B-897D-513CFEC346E5Q40754916-811B7973-DD83-49B9-B81D-C7786507693FQ40991139-91EA4AFD-490C-4CE0-9231-A7DB67914BB0Q42199922-F0F2D05A-092F-4C75-9548-FF9F1F4F3678Q44452669-BE584800-3A99-4B22-B18E-E4DFD1FD7DDAQ45751073-4BD5918D-1374-4FF7-8729-34EA737F9B83Q55240179-A83E3F2B-FE29-4888-8981-88968A604384Q55240592-FC1E5C22-94DB-43C5-99F5-4DCCC6E14724Q55240833-B0317209-8A4C-462B-83CA-041942735A75
P2860
Seroprevalence of HTLV-1 and HTLV-2 among intravenous drug users and persons in clinics for sexually transmitted diseases.
description
1992 nî lūn-bûn
@nan
1992年の論文
@ja
1992年学术文章
@wuu
1992年学术文章
@zh
1992年学术文章
@zh-cn
1992年学术文章
@zh-hans
1992年学术文章
@zh-my
1992年学术文章
@zh-sg
1992年學術文章
@yue
1992年學術文章
@zh-hant
name
Seroprevalence of HTLV-1 and H ...... sexually transmitted diseases.
@en
Seroprevalence of HTLV-1 and H ...... sexually transmitted diseases.
@nl
type
label
Seroprevalence of HTLV-1 and H ...... sexually transmitted diseases.
@en
Seroprevalence of HTLV-1 and H ...... sexually transmitted diseases.
@nl
prefLabel
Seroprevalence of HTLV-1 and H ...... sexually transmitted diseases.
@en
Seroprevalence of HTLV-1 and H ...... sexually transmitted diseases.
@nl
P2093
P921
P1476
Seroprevalence of HTLV-1 and H ...... sexually transmitted diseases.
@en
P2093
Hartley TM
Khabbaz RF
Onorato IM
P304
P356
10.1056/NEJM199202063260604
P407
P577
1992-02-01T00:00:00Z